8-K: Ocular Therapeutix Announces Positive Progress in Wet AMD Trials and Strong Financial Position

Ocular Therapeutix reports positive progress in its Phase 3 trials for AXPAXLI in wet AMD, with SOL-1 expected to be fully randomized by year-end 2024 and a strong cash balance to fund operations into 2028.

Summary

• Ocular Therapeutix announced its third quarter 2024 financial results and provided updates on its clinical programs.
• The company's Phase 3 SOL-1 trial for AXPAXLI in wet AMD is expected to be fully randomized by the end of 2024, ahead of previous guidance.
• Topline data from the SOL-1 trial is anticipated in the fourth quarter of 2025.
• Direct enrollment into the SOL-R trial is now open, streamlining the process for eligible subjects.
• The FDA has confirmed that the SOL-R trial is suitable as a second adequate study for a potential New Drug Application (NDA).
• Ocular Therapeutix reported a cash balance of $427.2 million as of September 30, 2024, which is expected to fund operations into 2028.
• Total net revenue for the third quarter of 2024 was $15.4 million, a 2.3% increase compared to $15.1 million in the same period of 2023.
• The company expects full-year 2024 total net revenues for DEXTENZA to be between $62.0 million and $67.0 million, compared to $57.9 million in 2023.
• Research and development expenses increased to $37.1 million in Q3 2024, up from $15.0 million in Q3 2023, due to increased clinical trial activity.
• The net loss for the third quarter of 2024 was $(36.5) million, or $(0.22) per share, compared to a net loss of $(0.5) million, or $(0.01) per share in the same period of 2023.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the accelerated timelines for the SOL-1 trial, the opening of direct enrollment for SOL-R, the FDA's positive feedback on SOL-R, and the strong cash position. However, the increased net loss and R&D expenses temper the overall optimism.

Positives

• The SOL-1 trial is progressing faster than expected, with full randomization anticipated by the end of 2024.
• The opening of direct enrollment for the SOL-R trial streamlines the patient recruitment process.
• The FDA's confirmation of the SOL-R trial's suitability for an NDA is a positive regulatory milestone.
• The company's strong cash balance of $427.2 million provides financial stability and runway into 2028.
• DEXTENZA revenue is growing, with a 2.3% increase in Q3 2024 and projected full-year revenue between $62.0 million and $67.0 million.

Negatives

• The company reported a net loss of $(36.5) million for the third quarter of 2024, a significant increase compared to the $(0.5) million loss in the same period of 2023.
• Research and development expenses have increased substantially to $37.1 million in Q3 2024, reflecting the high cost of clinical trials.
• Selling and marketing expenses increased to $10.6 million in Q3 2024, up from $9.3 million in Q3 2023.
• General and administrative expenses also increased to $12.2 million in Q3 2024, compared to $8.6 million in Q3 2023.

Risks

• The company's future success is heavily dependent on the outcomes of the SOL-1 and SOL-R clinical trials.
• There is a risk that the FDA may not agree with the company's interpretation of the Special Protocol Assessment for the SOL-1 trial.
• The FDA may not agree that the SOL-R trial data supports marketing approval, even if the trials are successful.
• The company's ability to grow DEXTENZA revenues in accordance with forecasts is not guaranteed.
• The company's financial performance is subject to uncertainties inherent in estimating cash runway and future expenses.

Future Outlook

The company anticipates an important milestone year in 2025 with the topline data from the SOL-1 trial expected in the fourth quarter. They also expect to continue to advance the development of AXPAXLI and other product candidates and aim to become a leader in retinal care. The company believes its current cash balance is sufficient to support its planned expenses, obligations, and capital expenditure requirements into 2028.

Management Comments

• Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer of Ocular Therapeutix, stated that the company is making outstanding progress on enrollment in the SOL-1 and SOL-R trials.
• Dr. Dugel also mentioned that SOL-1 and SOL-R were strategically designed to de-risk clinical outcomes, align with regulatory standards, enhance each other's enrollment, and provide a broad evaluation of AXPAXLI's durability, repeatability, and flexibility.
• Dr. Dugel noted that the company has enrolled SOL-1 faster than expected due to strong execution and relationships in the retina community.

Industry Context

This announcement is significant in the context of the competitive landscape for wet AMD treatments. Ocular Therapeutix is advancing its AXPAXLI program, which aims to provide a more durable and less frequent treatment option compared to current therapies that require frequent injections. The company's progress in clinical trials and its strong financial position position it as a potential key player in the retinal disease market.

Comparison to Industry Standards

• The SOL-1 trial's design, with a Special Protocol Agreement (SPA) with the FDA, is similar to other pivotal trials in the wet AMD space, such as those conducted by Regeneron for Eylea and Roche for Vabysmo.
• The SOL-R trial's focus on repeat dosing and flexible treatment regimens aligns with the industry's move towards more patient-friendly treatment options, similar to the approach taken by companies like Kodiak Sciences with their tarcocimab program.
• The reported cash balance of $427.2 million is substantial for a company of Ocular Therapeutix's size and stage, providing a competitive advantage compared to smaller biotech companies that may face funding challenges.
• The projected DEXTENZA revenue of $62.0 million to $67.0 million for 2024 is a positive sign of commercial traction, but it is still relatively small compared to the blockbuster sales of established wet AMD treatments like Eylea and Lucentis.

Stakeholder Impact

• Shareholders will be encouraged by the positive clinical trial progress and strong financial position.
• Employees will benefit from the company's growth and financial stability.
• Patients with wet AMD may have access to a new treatment option if AXPAXLI is approved.
• Customers of DEXTENZA will continue to have access to the product for ocular inflammation and pain.

Next Steps

• Complete randomization of the SOL-1 trial by the end of 2024.
• Continue enrollment in the SOL-R trial.
• Prepare for topline data from the SOL-1 trial in the fourth quarter of 2025.
• Advance the development of AXPAXLI and other product candidates.
• Continue to grow DEXTENZA revenues.

Key Dates

Keywords

Ocular Therapeutix, AXPAXLI, wet AMD, SOL-1, SOL-R, DEXTENZA, clinical trials, FDA, New Drug Application, retinal diseases, biopharmaceutical